Response of Fibroblastic Rheumatism to Infliximab

Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules, and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably to infliximab therapy. After 32 weeks of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Romiti, Ricardo, Levy Neto, Mauricio, Menta Simonsen Nico, Marcello
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879224/
https://www.ncbi.nlm.nih.gov/pubmed/20585484
http://dx.doi.org/10.1155/2009/715729
_version_ 1782181904669212672
author Romiti, Ricardo
Levy Neto, Mauricio
Menta Simonsen Nico, Marcello
author_facet Romiti, Ricardo
Levy Neto, Mauricio
Menta Simonsen Nico, Marcello
author_sort Romiti, Ricardo
collection PubMed
description Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules, and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably to infliximab therapy. After 32 weeks of continuous treatment, skin lesions dramatically improved and arthropathy partially regressed.
format Text
id pubmed-2879224
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28792242010-06-28 Response of Fibroblastic Rheumatism to Infliximab Romiti, Ricardo Levy Neto, Mauricio Menta Simonsen Nico, Marcello Dermatol Res Pract Case Report Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules, and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably to infliximab therapy. After 32 weeks of continuous treatment, skin lesions dramatically improved and arthropathy partially regressed. Hindawi Publishing Corporation 2009 2010-02-01 /pmc/articles/PMC2879224/ /pubmed/20585484 http://dx.doi.org/10.1155/2009/715729 Text en Copyright © 2009 Ricardo Romiti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Romiti, Ricardo
Levy Neto, Mauricio
Menta Simonsen Nico, Marcello
Response of Fibroblastic Rheumatism to Infliximab
title Response of Fibroblastic Rheumatism to Infliximab
title_full Response of Fibroblastic Rheumatism to Infliximab
title_fullStr Response of Fibroblastic Rheumatism to Infliximab
title_full_unstemmed Response of Fibroblastic Rheumatism to Infliximab
title_short Response of Fibroblastic Rheumatism to Infliximab
title_sort response of fibroblastic rheumatism to infliximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879224/
https://www.ncbi.nlm.nih.gov/pubmed/20585484
http://dx.doi.org/10.1155/2009/715729
work_keys_str_mv AT romitiricardo responseoffibroblasticrheumatismtoinfliximab
AT levynetomauricio responseoffibroblasticrheumatismtoinfliximab
AT mentasimonsennicomarcello responseoffibroblasticrheumatismtoinfliximab

Ejemplares similares